# *Index*

activity-based funding. *See* diagnosis-related group (DRG) funding
advance market commitments (AMCs), 647–9, 652
adverse selection principle of health insurance, 5, 12, 74, 92–4, 102
Afghanistan, 68
African Development Bank, 123
ageing populations, 44, 52–5, 246, 479, *See also* long-term care (LTC)
Albania, 371
alcohol, taxes on, 48–9, 50–1, 55, 526–8
AMCs (advance market commitments), 647–9, 652
AMR Action Fund, 586, 597
antibiotics, R&D funding
  additional resources, 603–4
  alternative antibacterial therapies, 594–5
  antimicrobial resistance (AMR), causes and effects, 573–4
  barriers to, 576–9
  European initiatives, 586–8
  global coordinating body, need for, 601–2
  incentivizing, 579–82, 595, 596–600
  key messages, xlix–l, 19, 572, 602–3
  lack of innovation concern, 574–5, 593–4
  multilateral initiatives, 582–6
  national initiatives, 588–90
  over-prescription disincentives, 205, 206, 207–8
  overview of initiatives, 582
  regulatory initiatives, 590–1, 597–8
  subscription payment models, 436, 590, 600–1
  WHO priority pathogens list, 592
  *See also* medicines procurement; pharmaceutical industry's R&D
Argentina, 498, 520–1, 552
Armenia, 43, 49, 69
Asian Development Bank, 119, 123, 125–7
ATMPs (gene therapies), 407, 415, 424, 436
Australia
  hospital care funding, 337, 343–4
  long-term care, 275, 495, 498
  low-value care decommissioning, 199, 201
  medicines procurement, 425
  pharmacist services, 296
  programme budgeting, 555–6
  public financing of healthcare, 38
  VHI schemes, 101, 103
Austria
  long-term care, 254–7, 268, 269
  medicine payments, 423
  user charges, 237

Bangladesh
  CBHI schemes, 68, 72
  old-age dependency ratios, 54
  public financing of healthcare, 39, 45, 49
BBBS open-source dividend, 657
Belarus, 423
Belgium
  long-term care, 254, 268, 269
  pharmacist services, 296
  public financing of healthcare, 38, 48
  user charges, 237
Belize, 520
benefits packages. *See* health benefits package (HBP) setting



https://doi.org/10.1017/9781009746274.022 Published online by Cambridge University Press

Beneluxa Initiative, 437
Benin, 68, 70
Bill & Melinda Gates Foundation, 521, 584, 638
block contracts for hospital care, 332–4, 340
Blue Cross Blue Shield Association, 207
Bosnia and Herzegovina, 371
Brazil
  ageing population challenge, 52, 53
  COVID-19 pandemic response, 552
  health benefits package, 520–1
  public financing of healthcare, 39, 44
  VHI schemes, 108
bribes. *See* informal payments
Bulgaria, 118, 427, 498
bundled payments
  for integrated care, 301–2, 460–3, 465–6, 468–9
  for long-term care, 486–7, 498–9
Burkina Faso, 68, 69, 70, 73, 74, 146
Burundi, 38

Cambodia, 46, 73
Cameroon, 49
Canada
  long-term care, 269, 490–1, 496–7
  low-value care decommissioning, 200, 201, 202
  pharmacist services, 296
  primary care commissioning, 299, 302–3
  public financing of healthcare, 38
  VHI schemes, 95, 101, 103, 109
cancer drug investments, 415–16, 430
capitation mechanisms
  bundled types. *See* bundled payments
  generally, xliii
  global or pooled types. *See* global or pooled payments
  for hospital care, 333
  for long-term care, 498–9
  for pharmacists, 296, 297
  for primary care, 18, 288, 290–1, 298
  rationing incentives, 15
  for risk sharing, 206–7
CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator), 585, 596, 597
carers, informal. *See* informal carers
case mix funding for hospital care, 175–6, 334–7, 339, 341
CBHI. *See* community-based health insurance (CBHI)
Chile
  health benefits package, 179–83, 191
  long-term care, 498
  VHI schemes, 109, 111, 179–80, 520–1
China
  ageing population challenge, 52, 53
  CBHI schemes, 68, 70
  informal payments in, 369, 370, 386
  medical savings accounts, 5
  pharmacist services, 296
  public financing of healthcare, 38
  user charges abolition, 231
clinical decision support tools, 207–8
clinical trials, concerns over, 416–17
Cochrane Library, 199
Colombia, 149
Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), 585, 596, 597
community pharmacists, 296–7
community-based care for older people, 252–3, 479, 483, 502–3, *See also* long-term care (LTC)
community-based health insurance (CBHI)
  additional resources, 80
  arguments supporting, 64–5, 66–7
  challenges, 70–1
  definition and characteristics, 5, 63–4, 65, 67
  externally sponsored schemes, 67–9
  impact, mixed evidence on, 69–70
  key messages, xxxv–xxxvi, 9, 63, 79–80
  preconditions for success, 75–8
  UHC delivery via, 78–9
  *See also* voluntary health insurance (VHI)
complementary and supplementary health insurance, 5, 31, 93–5, 105–7, 110–11, 145
consumption taxes. *See* indirect taxation
coordinated care. *See* integrated care, payment mechanisms

https://doi.org/10.1017/9781009746274.022 Published online by Cambridge University Press

co-payments. *See* user charges
Costa Rica, 33, 38, 49
cost-sharing arrangements. *See* user charges
Côte d'Ivoire, 68
COVID-19 pandemic
  health spending in, 20, 100–1
  health-related inequities in, 130, 541
  informal payments in, 369, 395, 397–8
  lessons from. *See* pandemic preparedness
  LTC sector deficiencies exposed in, 276–7
  ODA in. *See* official development assistance (ODA) for health
  vaccines developed in, 408, 438, 559–60
'cream-skimming'. *See* moral hazard problems
Croatia
  long-term care, 263, 268
  public financing of healthcare, 38
  VHI schemes, 95, 105–6
Cyprus, 101, 237, 423, 427
Czechia
  long-term care, 254–7, 498, 501
  low-value care decommissioning, 205

daily fees, 495–7
data protection, regulatory, 409
day care for older persons, 497, *See also* long-term care (LTC)
decentralized administrations, 146, 174–6, 189–90
decommissioning decisions. *See* low-value care decommissioning
Democratic Republic of the Congo
  CBHI schemes, 68, 71–2, 73
  Ebola epidemic in, 532
  health spending, 38, 45
  tax revenues, 46
demographic trends
  ageing populations, 44, 52–5, 246, 479
  long-term care recipients, 271–2
  single-adult households, 246–7
  *See also* long-term care (LTC)
Denmark
  ageing population challenge, 55
  health benefits package, 190, 427
  long-term care, 269, 498
  low-value care decommissioning, 205, 208
  medicines procurement, 432–3
  pharmacist services, 296
  primary care commissioning, 299
  public financing of healthcare, 36, 38
developed countries. *See* high-income countries (HICs); upper-middle-income countries (UMICs)
developing countries. *See* low- and middle-income countries (LICs and LMICs)
development assistance. *See* official development assistance (ODA) for health
devolved administrations, 146, 174–6, 189–90
diagnosis-related group (DRG) funding
  generally, 455
  German case study, 175–6
  for hospital care, 334–7, 339, 341
  for integrated care, 458, 471–2
  for long-term care, 485, 494
disinvestment decisions. *See* low-value care decommissioning
donations. *See* external health financing
Drugs for Neglected Diseases initiative, 415
drugs, payments for. *See* medicines procurement

Ebola epidemic (2014), 532, 554, 560, *See also* pandemic preparedness
Ecuador, 520
EDCTP (European and Developing Countries Clinical Trial Partnership), 585
efficiency concept, 35
Egypt, 39, 51
elderly persons, LTC needs. *See* long-term care (LTC)
EMA (European Medicines Agency), 408, 590–1, 597–8
employment-based risk pools, 145–6
England. *See* United Kingdom
equitable healthcare provision
  CBHI schemes and, 69, 78

https://doi.org/10.1017/9781009746274.022 Published online by Cambridge University Press

COVID-19 pandemic affecting, 130, 541
definition, 3
financial exclusion categories, 66–7
long-term care, challenges affecting, 275–8, 505
medicine price disparities, 433–4, 437
moral hazard problems affecting. *See* moral hazard problems
neglected diseases and. *See* neglected diseases, R&D funding
OOP payments, equity concerns, 7, 22, 65–6
informal payments, 394
user charges. *See* user charges, unintended effects
patient decision-making support, 205–6, 209–10
population groups covered by risk pools, 11
regressive v. progressive revenue raising, 7, 34–5, 92–4
risk pooling deficiencies affecting, 139, 140
UHC goal. *See* universal health coverage (UHC)
VHI, equity concerns. *See under* voluntary health insurance (VHI)
Estonia, 36, 264, 269, 495
Ethiopia
CBHI schemes, 69, 70, 74, 77, 78–9
old-age dependency ratios, 53
public financing of healthcare, 39, 45, 46
European and Developing Countries Clinical Trial Partnership (EDCTP), 585
European Health Preparedness and Response Authority (HERA), 588
European Medicines Agency (EMA), 408, 590–1, 597–8
European Union
access to drugs initiatives, 415, 417, 438
antibiotics initiatives, 586–8, 596
health financing, 7
long-term care needs studies, 270
medicines expenditure in, 426–7, 434
neglected diseases, R&D funding, 618
pharmaceuticals legislation, 410, 416
Vaccine Prize, 652
Evidence-Based Interventions programme (NHS England), 211–14
external health financing
CBHI schemes, externally sponsored, 67–9
generally, 7, 20
horizontal priority-setting and, 528–9, 535
neglected diseases R&D, grants and subsidies, 638
from NGOs, 521, 522–3
ODA. *See* official development assistance (ODA) for health
procurement systems of donors, 530–1
risk pooling approaches for, 150–1, 159
external reference pricing for medicines, 431–2

fee-for-service (FFS) mechanisms
generally
for hospital care, 331–2, 335, 338–9, 340
for integrated care, 458, 469, 471–2
for long-term care, 492–4, 498
over-provision incentives, 15, 170, 192, 211
for pharmacists, 296
for primary care, 18, 288, 291–2, 298–9, 302–3
financial hardship. *See* poverty
Finland
ageing population challenge, 55
long-term care, 262, 269
user charges, 236
fixed co-payments, 226, *See also* user charges
foreign direct investment, 123
France
Common Classification of Medical Procedures, 192
long-term care, 260
funding, 254, 262, 265, 274, 495
needs assessment, 269
low-value care decommissioning, 206

https://doi.org/10.1017/9781009746274.022 Published online by Cambridge University Press

France (cont.)
medicines procurement, 425, 427
public financing of healthcare, 38, 48, 55
VHI schemes, 95, 98

Gabon, 149
GAMRIF (Global Antimicrobial Resistance Innovation Fund), 585–6
GARDP (Global Antibiotic Research and Development Partnership), 584, 599
Gavi, the Vaccine Alliance, 518, 521, 523, 530–1
gene therapies (ATMPs), 407, 415, 424, 436
general taxation. *See* taxes and social health insurance (SHI)
Georgia, 46
Germany
health benefits package, 169, 174–6, 191, 192, 427
integrated care case study, 470–1
long-term care, 260, 269
funding, 262, 490, 497, 498, 500, 502–3
needs assessment, 268, 269
low-value care decommissioning, 201
pharmacist services, 296
public financing of healthcare, 38
user charges, 239
VHI schemes, 98–100, 103–4, 109, 111, 145
Ghana
CBHI schemes, 65, 68, 70, 78–9
pharmacist services, 296
public financing of healthcare, 48, 50–2, 144, 528
risk pooling approaches, 159
gifts. *See* informal payments
Global Antibiotic Research and Development Partnership (GARDP), 584, 599
Global Antimicrobial Resistance Innovation Fund (GAMRIF), 585–6
global financial crisis (2007–08), 100
Global Fund
financing and procurement strategies, 523, 524, 530, 535
role, 517–18, 521
specific programmes, 529, 560
Global Health Innovative Technology Fund, 638
global or pooled payments
for LTC. *See* long-term care (LTC), payment mechanisms
generally, 455
for hospital care, 333
for integrated care, 458–9
for pandemic preparedness, 549–50, 559–61
for primary care, 301
*See also* risk pooling
Great Britain. *See* United Kingdom
Greece
informal payments case study, 391–5
long term care, 249, 495
medicines procurement, 427
public financing of healthcare, 36, 391
user charges, 227
Guinea, 68, 70
Guyana, 46, 520

health benefits package (HBP) setting
additional resources, 193
decision-making framework, 188–93
disinvestment decisions. *See* low-value care decommissioning
explicit HBPs, case for and against, 168–70
explicit HBPs, examples, 170–1, 188
Chile, 179–83, 191
Germany, 174–6, 191, 192
Italy, 171–4, 190, 191
Malawi, 183–8, 190–1
Premera Blue Cross (US health insurer), 176–9
HBPs generally, 11, 166–8, 516–17
horizontal priority-setting for. *See* horizontal priority-setting
HTA for. *See* health technology assessment (HTA)
key messages, xxxix, 13, 165, 193
medicine choices. *See* medicines procurement
health financing
concept, xxxiii, 1
ethical concerns. *See* equitable healthcare provision

https://doi.org/10.1017/9781009746274.022 Published online by Cambridge University Press

functions overview, 2
horizontal priority-setting. *See* horizontal priority-setting
informal payments linked to, 386–7
key challenges, li–lii, 21–3
national comparisons, 19–21, 37–43
pooling function. *See* risk pooling
purchasing function, xlii, 13–15, 160, *See also* payment mechanisms; strategic resource allocation
revenue raising function, xxxiv, 4–7, *See also* community-based health insurance (CBHI); official development assistance (ODA) for health; taxes and social health insurance (SHI); voluntary health insurance (VHI)
UHC goal. *See* universal health coverage (UHC)
Health Impact Fund, 652
health insurance. *See* community-based health insurance (CBHI); voluntary health insurance (VHI)
health system efficiency concept, 35
health technology assessment (HTA)
for health benefits package setting, xxxix, 173, 190–1, 424–5
for identifying low-value care, xl, 199–200, 211
for medical devices, 173–4
for price control and regulation, 238, 407
for primary care payments, 292
healthcare as human right, 170
HERA (European Health Preparedness and Response Authority), 588
high-income countries (HICs)
health benefits packages (HBPs) in, 166, 167, 170, 191, 192
health financing, comparative data, 20–1
health spending in, 37–8, 49
informal payments in. *See* informal payments, prevalence
long-term care, spending on, 259–61
medicines expenditure in, 426–7
revenue raising challenges in, 31, 48–9, 52–5
VHI revenue in, 96
Honduras, 520–1
horizontal priority-setting
additional resources, 535–6
characteristics, 518–19
donor and country cooperation for, 528–9, 535
financing scheme integration for, 524–5
fiscal space expansion for, 524–8
funding arrangements affecting, 519–22
global health security linked to, 532–3
key messages, xlvii–xlviii, 18–19, 515–16
priority-setting generally, 516–18
procurement arrangements affecting, 522–4
procurement improvement for, 529–31
*See also* medicines procurement; pharmaceutical industry's R&D
hospital care, payment mechanisms
additional resources, 352
block contracts, 332–4, 340
choice factors
administrative effort, 340–2
number of hospitals, 338–9
number of payers, 338
relative importance of payer objectives, 339–40
compared, 328
diagnosis-related group (DRG), 334–7, 339, 341
fee-for-service (FFS), 331–2, 335, 338–9, 340
funding policy, key design elements, 323, 328
hospital objectives, 327
key messages, xliii–xliv, 15–18, 320–1, 351–2
line-item budgeting, 328–31, 339, 341
NHS England case study, 347–51
payer objectives
efficiency, 325–6
number and type of patients, 324
quality of care, 324–5
simplicity, 326
payer–hospital relationship, 321–3, 327
pay-for-performance (P4P), 345–6

https://doi.org/10.1017/9781009746274.022 Published online by Cambridge University Press

hospital care (cont.)
transitioning between, 342–5
HTA. *See* health technology assessment (HTA)
human right to healthcare, 170
Hungary, 48, 55

Iceland, 269, 336
IMF (International Monetary Fund), 45, 118, 119, 123
India
CBHI schemes, 68, 70, 73, 78–9
health spending, 49
informal payments in, 387
old-age dependency ratios, 54
public financing of healthcare, 36, 39, 44, 48
indirect taxation
alcohol and tobacco taxes, 48–9, 50–1, 55, 526–8
generally, 33, 35
VAT funding in Ghana, 528
Indonesia, 45, 146, 148–9, 296
ineffective care. *See* low-value care decommissioning
inequitable healthcare provision. *See* equitable healthcare provision
informal carers
cash and in-kind benefits for, 254–9, 502–3
concerns over, 250–2, 479
definition, 250
generally, xlvii, 485, 504
*See also* long-term care (LTC)
informal economic activity, 46–7, 144
informal payments
additional resources, 398
adverse effects on health systems, 363–4
data on, 20, 250
definitions, 362–3
drivers, empirical evidence, 367–71
drivers, theories, 365–7
generally, 5–6, 361–2
Greece case study, 391–5
key messages, xliv–xlv, 18, 360–1
motivations for, 363, 364–5
policy responses, 395–8
*See also* out-of-pocket (OOP) payments; user charges
informal payments, prevalence
Asia–Pacific region, 386
cross-sectional surveys, 372, 397
Europe, 368, 372–86
formal OOP payments and, 387–9
health financing levels and, 386–7
physician density and, 389–90
summary, 390–1
systematic review findings, 371–2
informed choice for patients, 205–6, 209–10
Innovative Medicines Fund, 424
Innovative Medicines Initiative, 414, 415, 587, 597
InnovFin Infectious Diseases Facility, 587
integrated care, payment mechanisms
additional resources, 473
bundled payments, 301–2, 460–3, 465–6, 468–9
Dutch case study, 468–9
German case study, 470–1
'integrated care' definition, 453–4
key messages, xlv–xlvi, 18, 452–3
operation in practice, 466–8
operation in theory, 465–6
overview of, 454–6
pay-for-coordination (P4C), 460, 465
performance objectives setting, 456–7
policy responses, 471–3
quality of care incentives, 464–5
shared-savings models, 463–4, 466, 469–70
traditional models, limitations, 458–9
US case study, 469–70
*See also* long-term care (LTC)
Inter-American Development Bank, 123
internal price referencing for medicines, 432
International Horizon Scanning Initiative, 438

https://doi.org/10.1017/9781009746274.022 Published online by Cambridge University Press

International Monetary Fund (IMF), 45, 118, 119, 123
Iran, 371
Ireland
  long-term care, 268, 275
  user charges, 236
  VHI schemes, 94, 109
Israel, 94, 491
Italy
  ageing population challenge, 55
  health benefits package, 171–4, 190, 191, 423, 424, 431
  long-term care, 268, 269, 486
  low-value care decommissioning, 205
  public financing of healthcare, 36, 38
Ivory Coast, 68

Japan
  ageing population challenge, 53,
  health spending, 49
  hospital care funding, 337
  informal payments in, 387
  long-term care, 257, 260, 269, 495, 498, 500
  pharmacist services, 296
  public financing of healthcare, 38
  user charges, 234
Joint Programming Initiative on Antimicrobial Resistance (JPIAMR), 584, 596
Jordan, 100

Kazakhstan, 423
Kenya, 68, 109, 146, 231
Kiribati, 43
Korea, Republic of
  hospital care funding, 337
  long-term care, 257, 500
  pharmacist services, 296
  public financing of healthcare, 39
  risk pooling approaches, 148–9, 157
Kosovo, 371
Kyrgyzstan, 146, 336, 423

Lao People's Democratic Republic, 68, 73
Latvia, 238–9, 263, 269, 427
Lebanon, 101
Liberia, 46, 101, 103
LICs and LMICs. *See* low- and middle-income countries (LICs and LMICs)
line-item budgeting for hospital care, 328–31, 339, 341
Lithuania, 227, 268–9, 498
lobbying by pharmaceutical industry, 412–13
Longitude Prize, 652
long-term care (LTC)
  additional resources, 279, 506
  decisions to apply for, 265–7, 272
  definition, 247–8
  formal carers, 248–50, 479–80
  funding 'carve outs' for, 11, 12, 262
  increasing demand for, 246–7, 479
  informal carers. *See* informal carers
  integrated care. *See* integrated care, payment mechanisms
  key messages, xli–xlii, 18, 245–6
  moral hazard problems, 504–5
  needs assessments
    national variations, 267–9
    reports on, 270
    within countries, 269–70
  OOP payments for, 261–5
  payment mechanisms. *See* long-term care (LTC), payment mechanisms
  public v. private provision, 253–4
  quality and value concerns, 275–8, 487–8, 504
  recipients, data on, 271–3
  services, 482
  settings for, 252–3, 482–3
  spending on, 259–61
long-term care (LTC), payment mechanisms
  budgets, 501
  bundled payments, 486–7, 498–9
  for community care, 502–3
  for day care, 497
  experimental schemes, 273–5, 487
  fee-for-service (FFS), 492–4, 498
  financial flows, 259, 480–1
  health care and LTC markets compared, 484–9, 503–6
  incentives created by, 492–5
  for institutional care, 495–501

https://doi.org/10.1017/9781009746274.022 Published online by Cambridge University Press

long-term care (LTC) (cont.)
key messages, xlvi–xlvii, 478–80, 503–6
pay-for-performance (P4P), 486–7, 499–501
per diem payments, 495–7
pooled payments, 487
allocation decisions, 491–2
collectors and payer agencies, 490–1
low- and middle-income countries (LICs and LMICs)
antibiotics overuse in, 573
CBHI systems advocated for. *See* community-based health insurance (CBHI)
external health financing for. *See* external health financing; official development assistance (ODA) for health
health benefits packages (HBPs) in, 166, 167, 183, 191
health financing, comparative data, 20–1, 38
health spending in, 37–8, 49, 427, 433–4, 437, 522
horizontal priority setting goal for. *See* horizontal priority-setting
neglected diseases in, 612
OOP payments levied in, 41–3, 65–6, 239, 367–8, 421
informal payments. *See* informal payments, prevalence
P4P mechanisms, potential benefits in, 306, 309, 311
pandemic preparedness planning by. *See* pandemic preparedness
revenue raising challenges in, 21–2, 31, 43–7, 53–4
risk pooling deficiencies in, 139, 142–3, 151, 157
VHI revenue in, 96
low-value care decommissioning
additional resources, 215
barriers to, 209–11
conceptual framework, 197–8
demand-side interventions, 202
financial, 203–5
nonfinancial, 205–6
identifying candidates for disinvestment, 198–201
key messages, xxxix–xl, 196–7, 214–15
multicomponent interventions, 208–9
NHS England case study, 211–14
prioritizing candidates for disinvestment, 201–2
supply-side interventions, 202
financial, 206–7
nonfinancial, 207–8
user charges as strategy, 203–5, 229–30
*See also* health technology assessment (HTA)
LTC. *See* long-term care (LTC)
Luxembourg, 262, 269, 427

Madagascar, 38
Malawi, 183–8, 190–1
Maldives, 387
Mali, 68, 69, 73, 79
managed-entry agreements for medicines, 430–1
market exclusivity/protection, 410
market failures. *See* moral hazard problems
marketing by pharmaceutical industry, 412–13
medical devices evaluations, 173–4
medical research, concerns over, 416–17
medical savings accounts (MSAs), 5
Medicare Shared Savings Program (US), 469–70
Medicines for Malaria Venture, 635–7
medicines procurement
additional resources, 439
antibiotics. *See* antibiotics, R&D funding
ATMPs (gene therapies), 407, 415, 424, 436
centralized tendering, 432–3
co-payments, 421–2
decision-making mechanisms, 173, 424–6
expenditure, comparative data, 426–7, 433–4
expenditure, composition of, 426
generally, 419–20
key messages, xlv, 18, 405–7
negative lists, 191

https://doi.org/10.1017/9781009746274.022 Published online by Cambridge University Press

over-prescription disincentives, 205–6, 207–8
payment mechanisms, 422, 427–9, 430–2, 436–7
policy responses, 435–9
Premera Blue Cross formulary, 176–9
prescription charges. *See* user charges
public funds, 420–1, 422–4
R&D investments. *See* pharmaceutical industry's R&D
repurposing of medicines, 418
safety controls, 531
subscription ('Netflix') model, 436, 590, 600–1
mental health services, 11, 146, 521
Mexico
ageing population challenge, 52
COVID-19 pandemic response, 556
public financing of healthcare, 44
risk pooling approaches, 147, 149, 157, 158
migrant workers in LTC sector, 250, 479–80
Moldova, 146, 423, 427
Monaco, 101
moral hazard problems
of CBHI schemes, 74
of DRG funding, 337
of long-term care, 504–5
neglected diseases R&D affected by, 624–5
pandemic preparedness affected by, 545–6
of user charges, 229–30
of VHI schemes, 101–2
Morocco, 49, 100
Mozambique, 146
MSAs (medical savings accounts), 5
multidisciplinary care. *See* integrated care, payment mechanisms
multilateral development bank finance. *See* official development assistance (ODA) for health
Myanmar, 36, 43

Namibia, 103
National Health Accounts, comparative data from, 19–21
National Health Service (NHS). *See* United Kingdom
neglected diseases, R&D funding
additional resources, 662
advance market commitments (AMCs), 647–9, 652
data on, 616
fiscal incentives, 641–5, 660
grants and subsidies, 638
inequities of, 619–20, 622, 624
key messages, l–li, 19, 611–12, 653–62
market failures affecting, 624–5
neglected diseases generally, 612, 615
patent buyouts, 645–6
priority review vouchers (PRVs), 646–7
prizes, 652–3
product development partnerships (PDPs) for, 630–5, 637
push and pull incentive mechanisms, 413–15, 626–7, 660–1
recipients, 619
sources of, 618–19
transferable patent extensions, 645
WHO initiatives, 615–16, 661–2
*See also* pharmaceutical industry's R&D
Nepal, 68
'Netflix' model of medicines procurement, 436, 590, 600–1
Netherlands
ageing population challenge, 55
compulsory health insurance, 34
integrated care case study, 468–9
long-term care, 260
funding, 257–9, 486–7, 501
needs assessment, 268, 488
low-value care decommissioning, 201, 205
pharmacist services, 296
primary care commissioning, 302
public financing of healthcare, 100, 147–8
VHI schemes, 95, 109, 111, 145
New Zealand, 201, 296, 337, 556,
NGO health financing. *See* external health financing
NHS. *See* United Kingdom

https://doi.org/10.1017/9781009746274.022 Published online by Cambridge University Press

Nigeria
old-age dependency ratios, 53
public financing of healthcare, 36, 39, 44, 45, 47, 51
risk pooling approaches, 146, 523
supply chain management, 530, 547–8
Nordic Pharmaceutical Forum, 437
Norway
health spending, 38, 431
long-term care, 249, 269
primary care commissioning, 299
public financing of healthcare, 36, 38

OECD Development Assistance Committee (DAC), 118, 119, 123, 131
official development assistance (ODA) for health
additional resources, 131
Asian Development Bank's COVID response, 125–7
critical role played by, 122–3
definition, 118
key messages, xxxvi–xxxvii, 10, 116–18, 130–1
multilateral development banks' role, 123–5, 550
for pandemic preparedness, 122, 129–30, 550, 552–3
quality and impact assessments, 127–9
recipients, COVID impact, 120–1
volumes and donors, COVID impact, 118–20, 121–2
*See also* external health financing; pandemic preparedness
old-age dependency ratios, 52–5, 246
older persons, LTC needs. *See* long-term care (LTC)
One Health framework, 561, *See also* pandemic preparedness
out-of-pocket (OOP) payments
CBHI schemes, impact on, 70
equity concerns, 7, 22, 65–6
informal payments, 394
user charges. *See* user charges, unintended effects
as horizontal priority-setting strategy, 526
for long-term care, 261–5
P4P mechanisms to reduce, 306
private health sector and, 370
public finance increases, effects on, 40–1, 103, 111
revenue from, national comparisons, 41–3
risk pooling implications, 139–40, 142–3
types. *See* informal payments; user charges
VHI schemes compared with, 94

P4C (pay-for-coordination) mechanisms, 460, 465, 487–8, *See also* integrated care, payment mechanisms
P4P. *See* pay-for-performance (P4P) mechanisms
Pakistan, 39, 45, 49
Panama, 49
Pandemic Emergency Finance Facility (World Bank), 561
pandemic preparedness
accountability goal, 557
additional resources, 565
definition, 543–5
domestic resources and national mechanisms, 550–2, 557–9
European Union agency (HERA), 588
external assistance, 122, 129–30, 550, 552–3
financing challenges, 546–9
flexible financial management goal, 553–7
horizontal priority-setting and, 532–3
international guidance, xlix, 547, 551
introduction, 541–3
key messages, xlviii–xlix, 19, 540–1, 564–5
moral hazard problems, 545–6
pooled financing at global level for, 549–50, 559–61
Viet Nam case study, 562–4

https://doi.org/10.1017/9781009746274.022 Published online by Cambridge University Press

World Bank mechanisms, 560
*See also* COVID-19 pandemic; official development assistance (ODA) for health
patents for medicines, 645–6
patients
decision-making support, 205–6, 209–10
older persons. *See* long-term care (LTC)
payments by. *See* informal payments; out-of-pocket (OOP) payments; user charges
pay-for-coordination (P4C) mechanisms, 460, 465, 487–8, *See also* integrated care, payment mechanisms
pay-for-performance (P4P) mechanisms
for hospital care, 345–6
for integrated care, 464–5, 467
LMICs, potential benefits in, 306, 309, 311
for long-term care, 486–7, 499–501
low-value care decommissioning and, 206
for primary care
generally, 288, 292–4
quality improvement, 304–9, 310
secondary care reduction, 299–300, 302–3
UK QOF case study, 299–300
payment mechanisms
bundled. *See* bundled payments
co-payments. *See* user charges
generally, 484
global or pooled. *See* global or pooled payments
for integrated care. *See* integrated care, payment mechanisms
key principles for, lii
for LTC. *See* long-term care (LTC), payment mechanisms
for medicines, 422, 427–9, 430–2, 436–7
mixed methods, 18, 294, 310
overview of, 17
for primary care services. *See* primary care commissioning
for secondary care services. *See* hospital care, payment mechanisms
transitioning between, 342–5
*See also* capitation mechanisms; diagnosis-related group (DRG) funding; fee-for-service (FFS) mechanisms; pay-for-performance (P4P) mechanisms
per diem fees, 495–7
percentage-based co-payments, 226–7, *See also* user charges
personal care for older persons. *See* long-term care (LTC)
Peru, 149, 520–1
pharmaceutical industry's R&D
antibiotics research. *See* antibiotics, R&D funding
cost of, 417–19
in COVID-19 pandemic, 408, 411–12
early stage, public funding, 410–11
intellectual property rights, 410
lobbying and marketing activity, 412–13
neglected diseases. *See* neglected diseases, R&D funding
overview of phases, 407–8
policy responses, 434–5
push and pull incentive mechanisms, 413–15, 626–7
unmet patient needs concern, 415–17, 624–5
*See also* medicines procurement
pharmacists, remuneration of, 296–7
Philippines
CBHI schemes, 68
old-age dependency ratios, 54
public financing of healthcare, 39, 49, 50–1
risk pooling approaches, 146
Poland, 249, 272, 427
pooled payments. *See* global or pooled payments
pooling concept, xxxvii, 10, 138–9, *See also* risk pooling
population trends. *See* demographic trends


https://doi.org/10.1017/9781009746274.022 Published online by Cambridge University Press

Portugal
ageing population challenge, 54
long-term care, 249, 269, 486, 497
pharmacist services, 296
public financing of healthcare, 36
poverty
low CBHI uptake due to, 71
OOP payments contributing to, 231–4, 236, 261–5, 332, 394, 421–2, 521
as revenue raising challenge, 44, 123
rural areas, 142
Premera Blue Cross (US health insurer), 176–9
prescription charges. *See* user charges
price control and regulation, 238, 407
primary care commissioning
additional resources, 311
generally, 286–7
information technology for, 292
integrated care. *See* integrated care, payment mechanisms
key messages, xliii, 15, 285, 309–11
organization of primary care, 286
payment models
compared, 290–4
mixed, 18, 294, 310
overview and effects of, 288–90
pharmacists' remuneration, 296–7
quality of care, effects of payment models, 303–9, 310
UK QOF case study, 299–300
for secondary care reduction
background, 294–8
effects of payment models, 298–303, 309–10
priority review vouchers, 646–7
priority-setting, horizontal. *See* horizontal priority-setting
private health insurance. *See* voluntary health insurance (VHI)
prizes for R&D innovation, 652–3
programme budgeting, 202, 326, 554–5, 556–7
public financing. *See* taxes and social health insurance (SHI)
public health emergency funding. *See* pandemic preparedness
purchasing healthcare services, xlii, 13–15, 160, *See also* payment mechanisms; strategic resource allocation

quality of care
definition, 3
disinvestment decisions. *See* low-value care decommissioning
hospital care, 324–5, 340, 345–6
integrated care, 464–5
long-term care, 275–8, 487–8, 504
moral hazard problems affecting. *See* moral hazard problems
primary care, effects of payment models, 303–9, 310
UK QOF case study, 299–300
QuODA index, 127–8, *See also* official development assistance (ODA) for health

R&D investments. *See* pharmaceutical industry's R&D
Regional Disease Surveillance Systems Enhancement (World Bank), 561
regional risk pools, 146
regulatory data protection, 409
Republic of Korea. *See* Korea, Republic of
research and development investments. *See* pharmaceutical industry's R&D
revenue raising, xxxiv, 4–7, *See also* community-based health insurance (CBHI); official development assistance (ODA) for health; taxes and social health insurance (SHI); voluntary health insurance (VHI)
right to health, 170
risk pooling
additional resources, 161
by communities. *See* community-based health insurance (CBHI)
employment-based pools, 145–6
fragmentation prevention strategies, 147–51
generally, 10–11, 22, 138–40
good system design, 140–1

https://doi.org/10.1017/9781009746274.022 Published online by Cambridge University Press

horizontal priority-setting, implications for, 523–4
key messages, xxxviii–xxxix, 12–13, 137–40, 159–61
one-pool systems, 145
overview of types, 143–5
pooling concept, xxxvii, 10, 138–9
poor system design, 142–3
reforms, political economy of, 156–9
reforms, Thailand case study, 147, 149, 151–6, 158
region-based pools, 146
services covered. *See* health benefits package (HBP) setting
for specialist services, 12, 146–7, 262
user charges. *See* user charges
*See also* global or pooled payments
Romania, 240
Russian Federation, 39, 44, 53, 54
Rwanda, 65, 69, 70, 78–9, 309

salary payments
generally, 455
in pandemics, 557–8
for primary care, 288, 290, 298
SDGs (Sustainable Development Goals), 64, 68, 117, 183, 516, 541
secondary care, payment for. *See* hospital care, payment mechanisms
Semashko model health service, 32
Senegal, CBHI schemes
administration, 75–6, 77
impact, 69, 70, 77
introduction, 68
state support, 68–9, 73, 75
Serbia, 371
shared-savings payment models, 463–4, 466, 469–70, 487–8, *See also* integrated care, payment mechanisms
SHI. *See* taxes and social health insurance (SHI)
Singapore, 5, 337
Slovakia
Slovenia, 95, 105–6, 238, 264
social care for older persons. *See* long-term care (LTC)
social health insurance. *See* taxes and social health insurance (SHI)
Solomon Islands, 43
South Africa
COVID-19 pandemic response, 556
medical savings accounts, 5
public financing of healthcare, 51
risk pooling approaches, 150, 157
VHI schemes, 94, 100, 103, 109, 148
South Korea. *See* Korea, Republic of
South Sudan, 38, 49
Spain
health benefits package, 190, 191, 423
long-term care, 486, 488, 496, 503
low-value care decommissioning, 201
public financing of healthcare, 36
user charges, 240
Sri Lanka, 49
strategic resource allocation
future challenges, 23
HBP setting. *See* health benefits package (HBP) setting
horizontal priority-setting. *See* horizontal priority-setting
pandemic preparedness. *See* pandemic preparedness
programme budgeting, 202, 326, 554–5, 556–7
transparent policies, 169–70
subscription model of medicines procurement, 436, 590, 600–1
substitutive health insurance, 96, 111
supplementary and complementary health insurance, 5, 31, 93–5, 105–7, 110–11, 145
supplementary protection certificates, 409
Suriname, 520
Sustainable Development Goals (SDGs), 64, 68, 117, 183, 516, 541
Sweden
antibiotics initiatives, 600–1
long-term care, 269, 487, 496
Switzerland
compulsory health insurance, 34
health spending, 38
long-term care, 272, 497

https://doi.org/10.1017/9781009746274.022 Published online by Cambridge University Press

Switzerland (cont.)
low-value care decommissioning, 208
pharmacist services, 296
user charges, 237
VHI schemes, 109, 145

Taiwan, 302
Tanzania, 68, 70, 73, 548
taxes and social health insurance (SHI)
additional resources, 57
ageing populations challenge, 44, 52–5, 246
conflicting budget priorities challenge, 49–52
defined and compared, 32–3, 35–7
equity, regressive v. progressive systems, 7, 34–5
fiscal incentives for R&D, 641–5, 660
generally, 30–2
increases, effects on OOP payments and VHI, 40–1, 103, 111
indirect taxation. *See* indirect taxation
informal economic activity challenge, 46–7
key messages, xxxiv–xxxv, 9, 29, 55–6
for long-term care, 259
low economic growth/poverty challenge, 44
medicine payments from. *See* medicines procurement
resistance to SHI contributions challenge, 47–9
revenue, national comparisons, 37–8, 39
variations between schemes, 4, 34
weak revenue generation challenge, 44–6
TB Alliance, 633
Thailand
alcohol and tobacco taxes, 528
health benefits package, 524–5
hospital care funding, 337
pharmacist services, 296
risk pooling reforms, 147, 149, 151–6, 158
VHI schemes, 100, 529
Tinbergen Rule, 343
tobacco, taxes on, 48–9, 50–1, 55, 526–8
Togo, 73
Transatlantic Task Force on Antimicrobial Resistance, 591
Turkey, 148–9, 157–8

Uganda, 49, 69, 146, 159
UHC. *See* universal health coverage (UHC)
Ukraine, 46, 423
UMICs. *See* upper-middle-income countries (UMICs)
United Arab Emirates, 101, 118
United Kingdom
access problems, 101
antibiotics initiatives, 585–6, 589–90, 596, 600–1
health and social care global budgets, 301
health benefits package, 168, 169, 190
hospital care funding, 347–51
long-term care, 260
funding, 275, 487
needs assessment, 269
low-value care decommissioning, 200, 201, 202, 206, 208, 211–14
medicines procurement, 424
neglected diseases, R&D incentives, 641–5, 660
NHS introduction, 32, 35
patient safety scandals, 346
pharmacist services, 296
prescription charges, 226
primary care commissioning, 299–300, 301
public financing of healthcare, 38, 48, 347
VHI schemes, 104, 520
United Nations
Development Programme (UNDP), 118, 123
pandemic preparedness guidance, 542
Sustainable Development Goals (SDGs), 64, 68, 117, 183, 516, 541
United States of America
ageing population challenge, 38, 53

https://doi.org/10.1017/9781009746274.022 Published online by Cambridge University Press

antibiotics initiatives, 588–9, 591, 596, 597–8, 601
compulsory health insurance, 100
health spending, 49, 197
long-term care
funding, 275, 496–7, 498–9, 500–1
needs assessment, 269
OOP payments, 264, 265
low-value care decommissioning, 201, 206, 207
medical savings accounts, 5
Medicare Shared Savings Program, 469–70
neglected diseases, R&D funding, 618, 638, 641, 645, 646–7, 660
pharmacist services, 296
Premera Blue Cross (health insurer), 176–9
primary care commissioning, 301, 302, 303
risk pooling approaches, 146
vaccine research in COVID-19 pandemic, 411
VHI schemes, 103, 109, 520
universal health coverage (UHC)
CBHI schemes for, 78–9
definition, 1
horizontal priority-setting for. *See* horizontal priority-setting
key financing challenges, li–lii, 21–3
optimal financing models for, 32, 40
policy designs for, 10–11
risk pooling design for. *See* risk pooling
Sustainable Development Goal 3.8 on, 64, 68, 183, 516
VHI and. *See* voluntary health insurance (VHI)
WHO guidelines on, 516
*See also* equitable healthcare provision
upper-middle-income countries (UMICs)
health financing, comparative data, 21
health spending in, 37–8
OOP payments levied in, 43
revenue raising challenges in, 52–5
VHI revenue in, 96
Uruguay, 49, 100, 498, 520
user charges
additional resources, 241
co-payments, 421–2
data on, 20
direct and indirect types, 13
examples of schemes, 238–9
fixed, percentage-based and mixed types, 226–7
generally, 5–6, 11–12, 421
key messages, xl–xli, 13, 224–6, 239–40
as low-value care disincentive, 203–5, 229–30
for primary care, 292
protective mechanisms, 234–8
revenue from, 230–1
*See also* informal payments; medicines procurement; out-of-pocket (OOP) payments; risk pooling
user charges, unintended effects
drug regimen nonadherence, 228–9
poverty, 231–4, 332, 421–2, 521
preventive care discouragement, 230
unmet health needs, 234
*See also* equitable healthcare provision

vaccines in COVID-19 pandemic, 408, 438, 559–60
Valletta Declaration, 437
value-added tax. *See* indirect taxation
value-based pricing for medicines, 428–9
value-for-money decisions
disinvestment decisions. *See* low-value care decommissioning
by donors, 530–1
HBP setting. *See* health benefits package (HBP) setting
for hospital care, 325–6
HTA for. *See* health technology assessment (HTA)
in long-term care sector, 277–8
for pandemic preparedness, 548–9
*See also* quality of care
Vanuatu, 43
VAT. *See* indirect taxation
Venezuela, 100
vertical priority-setting, 517–18, 532, *See also* horizontal priority-setting

https://doi.org/10.1017/9781009746274.022 Published online by Cambridge University Press

Viet Nam, 529, 562–4
voluntary health insurance (VHI)
  additional resources, 112–13
  adverse selection concern, 5, 12, 92–4, 102
  CBHI. *See* community-based health insurance (CBHI)
  complementary and supplementary types, 5, 31, 93–5, 105–7, 110–11, 145
  distorted use of resources concern, 148
  early forms, 102–3
  horizontal priority-setting, implications for, 520–1
  key messages, xxxvi, 91–2, 112
  medical savings accounts (MSAs), 5
  OOP payments compared with, 94
  policy responses, 110–12
  public finance increases, effects on, 103, 111
  resistance to regulation concern, 109–10
  revenue from
    changes over time, 96–101
    general data, 20, 38
    national comparisons, 96, 98,
  substitutive type, 96, 111
  UHC delivery via, overview of challenges, 9–10, 101
  unaffordability concern, 103–7
  for user charges reimbursement, 238

Wellcome Trust, 549, 584, 586, 638
WHO. *See* World Health Organization (WHO)
women
  formal workers in LTC sector, 250, 479–80
  informal workers in LTC sector. *See* informal carers
  long-term care (LTC) recipients, 271–2
World Bank
  ODA provision by, 119, 123
  pandemic preparedness guidance, xlix, 547
  pandemic preparedness mechanisms, 560, 561
  *See also* official development assistance (ODA) for health
World Health Organization (WHO)
  antibiotics work, 573, 592
  Contingency Fund for Emergencies, 559
  essential medicines guidelines, 423
  long-term care needs estimate, 270
  neglected diseases initiatives, 615–16, 661–2
  OOP threshold recommendation, 40
  pandemic preparedness guidance, xlix, 547, 551
  poverty definition, 232–3
  risk pooling guidance, 140–1, 154, 156, 160
  universal health coverage guidelines, 516

XPRIZE Foundation, 652

Zimbabwe, 74

https://doi.org/10.1017/9781009746274.022 Published online by Cambridge University Press